Olaparib (Olaparib, Lipadro) treatment indications for ovarian cancer

Lynparza (Olaparib, also known as Lipadrox) has shown significant efficacy in the treatment of ovarian cancer, and its indications mainly include the following aspects:

1.Maintenance treatment for advanced epithelial ovarian cancer:

Olaparib is mainly approved in China for the maintenance treatment of patients with advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who carry germline or somatic BRCA mutations. These patients typically achieve complete or partial response after first-line platinum-containing chemotherapy. Lynparza can prolong the survival and improve the quality of life of these patients.

2.Maintenance therapy for platinum-sensitive recurrent ovarian cancer:

Lynparza also showed good efficacy in the treatment of adult patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. After these patients achieve complete remission or partial remission with platinum-based chemotherapy, maintenance therapy with olaparib can be used to reduce the risk of recurrence.

3.Treatment of special subgroups of patients:

In addition to the above indications, olaparib can also be used for patients with HRD (homologous recombination repair deficiency)-positive advanced ovarian cancer. Such patients can be treated in combination with bevacizumab. In addition, olaparib can also be used as an adjuvant treatment option for high-risk breast cancer patients with BRCA and HR-positive breast cancer.

In terms of efficacy, Lynparza’s performance is impressive. For example, in a phase 3 clinical trial, olaparib was able to significantly extend the overall survival (OS) of patients with BRCA1/2 mutated platinum-sensitive recurrent ovarian cancer. Compared with the placebo group, the median OS of patients in the olaparib group was prolonged by 12.9 months, which fully demonstrates the effectiveness of olaparib in treating this type of patients.

It should be noted that although olaparib is effective, some adverse reactions may occur during use, such as nausea, vomiting, diarrhea, anemia, etc. Therefore, patients should use it under the guidance of a doctor and pay close attention to their physical condition.